Ryutaro Kotaki

Ryutaro Kotaki

Auto-generated profile, based on publicly available information

Ryutaro Kotaki

Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2022 in Science Immunology
Verified
Journal Article
Open access
RKRyutaro Kotaki
Ryutaro Kotaki
YAYu Adachi
Yu Adachi
SMSaya Moriyama
Saya Moriyama
TOTaishi Onodera
Taishi Onodera
SFShuetsu Fukushi
Shuetsu Fukushi
YTYoshimasa Takahashi
Yoshimasa Takahashi
Multiple SARS-CoV-2 variants have mutations in the spike receptor binding domain (RBD) with potential to evade neutralizing antibody. In particular, the Beta and Omicron variants escape from antibody neutralizing activity in those who received two doses of BNT162b2 mRNA vaccine. Nonetheless, boosting with a third vaccine dose or by breakthrough infection improves the overall breadth of the neutralizing antibodies, but the mechanism remains unclear. Here, we longitudinally profiled the cellular composition of RBD-binding memory B cell subsets and their antibody binding and neutralizing activity against SARS-CoV-2 variants after the second dose of mRNA vaccine. Two doses of the mRNA vaccine elicited plasma neutralizing antibodies with a limited activity against Beta and Omicron but induced an expanded antibody breadth overtime, up to 4.9 months after vaccination. In contrast, more than one-third of RBD-binding IgG + memory B cells with a resting phenotype initially bound the Beta and Omicron variants and steadily increased the B cell receptor breadth overtime. As a result, a fraction of the resting memory B cell subset secreted Beta and Omicron-neutralizing antibody when stimulated in vitro. The neutralizing breadth of the resting memory B cell subset helps us understand the prominent recall of Omicron-neutralizing antibodies after an additional booster or breakthrough infection in fully vaccinated individuals.

6 May 2022 in Science Immunology
Verified
Journal Article
Closed access
MKMasayuki Kuraoka
Masayuki Kuraoka
CYChen-Hao Yeh
Chen-Hao Yeh
GBGoran Bajic
Goran Bajic
RKRyutaro Kotaki
Ryutaro Kotaki
SSShengli Song
Shengli Song
GKGarnett Kelsoe
Garnett Kelsoe
Immunization or microbial infection can establish long-term B cell memory not only systemically but also locally. Evidence has suggested that local B cell memory contributes to early local plasmacytic responses after secondary challenge. However, it is unclear whether locality of immunization plays any role in memory B cell participation in recall germinal centers (GCs), which is essential for updating their B cell antigen receptors (BCRs). Using single B cell culture and fate mapping, we have characterized BCR repertoires in recall GCs after boost immunizations at sites local or distal to the priming. Local boosts with homologous antigen recruit the progeny of primary GC B cells to recall GCs more efficiently than do distal boosts. Recall GCs elicited by local boosts contain significantly more B cells with elevated levels of immunoglobulin (Ig) mutation and higher avidity BCRs. This local preference is unaffected by blocking CD40:CD154 interaction to terminate active, GC responses. Local boosts with heterologous antigens elicit secondary GCs with B cell populations enriched for cross-reactivity to the prime and boost antigens; in contrast, cross-reactive GC B cells are rare after distal boosts. Our results suggest that local B cell memory is retained in the form of memory B cells, GC B cells, and GC phenotype B cells that are independent of organized GC structures and that these persistent “primed B cells” contribute to recall GC responses at local sites. Our findings indicate the importance of locality in humoral immunity and inform serial vaccination strategies for evolving viruses.

1 June 2017 in Immunology
Verified
Journal Article
Closed access
PDF file
ASAya Shiokawa
Aya Shiokawa
RKRyutaro Kotaki
Ryutaro Kotaki
TTTomohiro Takano
Tomohiro Takano
HNHaruyo Nakajima‐Adachi
Haruyo Nakajima‐Adachi
SHSatoshi Hachimura
Satoshi Hachimura

14 July 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
SMSaya Moriyama
Saya Moriyama
YAYuki Anraku
Yuki Anraku
STShunta Taminishi
Shunta Taminishi
YAYu Adachi
Yu Adachi
DKDaisuke Kuroda
Daisuke Kuroda
YTYoshimasa Takahashi
Yoshimasa Takahashi
SARS-CoV-2 Omicron subvariants have evolved to evade receptor-binding site (RBS) antibodies that exist in diverse individuals as public antibody clones. We rationally selected RBS antibodies resilient to mutations in emerging Omicron subvariants. Y489 was identified as a site of virus vulnerability and a common footprint of broadly neutralizing antibodies against the subvariants. Multiple Y489-binding antibodies were encoded by public clonotypes and additionally recognized F486, potentially accounting for the emergence of Omicron subvariants harboring the F486V mutation. However, a subclass of antibodies broadly neutralized BA.4/BA.5 variants via hydrophobic binding sites of rare clonotypes along with high mutation-resilience under escape mutation screening. A computationally designed antibody based on one of the Y489-binding antibodies, NIV-10/FD03, was able to bind XBB with any 486 mutation and neutralized XBB.1.5. The structural basis for the mutation-resilience of this Y489-binding antibody group may provide important insights into the design of therapeutics resistant to viral escape.

21 August 2024 in Science Translational Medicine
Verified
Journal Article
Closed access
RKRyutaro Kotaki
Ryutaro Kotaki
SMSaya Moriyama
Saya Moriyama
SOShintaro Oishi
Shintaro Oishi
TOTaishi Onodera
Taishi Onodera
YAYu Adachi
Yu Adachi
YTYoshimasa Takahashi
Yoshimasa Takahashi
Immunological imprinting by ancestral SARS-CoV-2 strains is thought to impede the robust induction of Omicron-specific humoral responses by Omicron-based booster vaccines. Here, we analyzed the specificity and neutralization activity of memory B (B mem ) cells after repeated BA.5 exposure in individuals previously imprinted by ancestral strain–based mRNA vaccines. After a second BA.5 exposure, B mem cells with BA.5 spike protein–skewed reactivity were promptly elicited, correlating with preexisting antibody titers. Clonal lineage analysis identified BA.5-skewed B mem cells that had redirected their specificity from the ancestral strain to BA.5 through somatic hypermutations. Moreover, B mem cells with redirected BA.5 specificity exhibited accelerated development compared with de novo B mem cells derived from naïve repertoires. This redirected BA.5 specificity demonstrated greater resilience to viral point mutation and adaptation to recent Omicron variants HK.3 and JN.1, months after the second BA.5 exposure, suggesting that existing B mem cells elicited by older vaccines can redirect their specificity toward newly evolving variants.

15 March 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
TTTomohiro Takano
Tomohiro Takano
Takashi SatoTakashi Sato
Takashi Sato
RKRyutaro Kotaki
Ryutaro Kotaki
SMSaya Moriyama
Saya Moriyama
SFShuetsu Fukushi
Shuetsu Fukushi
YTYoshimasa Takahashi
Yoshimasa Takahashi
The immunogenicity of mRNA vaccines has not been well studied when compared to different vaccine modalities in the context of additional boosters. Here we show that longitudinal analysis reveals more sustained SARS-CoV-2 spike receptor-binding domain (RBD)-binding IgG titers with the breadth to antigenically distinct variants by the S-268019-b spike protein booster compared to the BNT162b2 mRNA homologous booster. The durability and breadth of RBD-angiotensin-converting enzyme 2 (ACE2) binding inhibitory antibodies are pronounced in the group without systemic adverse events (AEs) after the S-268019-b booster, leading to the elevated neutralizing activities against Omicron BA.1 and BA.5 variants in the stratified group. In contrast, BNT162b2 homologous booster elicited antibodies to spike N-terminal domain in proportion to the AE scores. High-dimensional immune profiling identifies early CD16+ natural killer cell dynamics with CCR3 upregulation, as one of the correlates for the distinct anti-RBD antibody responses by the S-268019-b booster. Our results illustrate the combinational effects of heterologous booster on the immune dynamics and the durability and breadth of recalled anti-RBD antibody responses against emerging virus variants.